GC4419: Phase Ib/IIa data

An open-label, dose-escalation, U.S. Phase Ib/IIa trial in 34 evaluable patients with head and neck cancer showed

Read the full 170 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE